- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Podcast: Getting Your Radiology Solution Out There
Paul Chang, MD, offers some advice and warns of a few pitfalls radiology professionals face when getting their home-grown IT tools into the market.
[[{"type":"media","view_mode":"media_crop","fid":"8023","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_5428327812734","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"208","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]]Radiology clinicians and researchers know the requirements of their work flow better than any vendor or marketing survey - so many are developing their own software. Today, it’s easier than ever to develop IT solutions, but there can be a lot of obstacles, says Paul Chang, MD, FSIIM, professor and vice chairman of radiology informatics at the University of Chicago School of Medicine.
In this podcast, the second in a two-part series, Chang previews some of the advice and guidance he’ll be giving at SIIM 2012 on how to get your solution into the market.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
